MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Medivation Company Profile (NASDAQ:MDVN)

Consensus Ratings for Medivation (NASDAQ:MDVN) (?)
Ratings Breakdown: 1 Sell Rating(s), 7 Hold Rating(s), 13 Buy Rating(s)
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $72.55 (27.39% upside)

Analysts' Ratings History for Medivation (NASDAQ:MDVN)
Show:
DateFirmActionRatingPrice TargetActions
6/16/2016BarclaysReiterated RatingOverweight$70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016BMO Capital MarketsReiterated RatingMarket Perform$47.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Jefferies GroupReiterated RatingHold$52.00 -> $56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2016Leerink SwannReiterated RatingMarket Perform$39.00 -> $64.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2016RBC CapitalReiterated RatingSector Perform$40.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/7/2016Brean CapitalReiterated RatingBuy$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Citigroup Inc.UpgradeNeutral -> Buy$37.00 -> $73.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Maxim GroupBoost Price TargetBuy$47.00 -> $76.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016MizuhoDowngradeNeutral -> Underperform$150.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2016Stifel NicolausBoost Price TargetBuy$52.00 -> $66.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016WedbushReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/1/2016Goldman SachsReiterated RatingNeutral$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016SunTrustReiterated RatingBuy$56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016Canaccord GenuityUpgradeHold -> Buy$45.00 -> $70.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/4/2016BTIG ResearchReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/19/2016Bank of AmericaInitiated CoverageBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/31/2016William BlairReiterated RatingOutperform$83.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/26/2015JMP SecuritiesLower Price TargetMarket Outperform$152.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2015NomuraInitiated CoverageBuy$140.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2015JPMorgan Chase & Co.Boost Price TargetOverweight$130.00 -> $148.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2014AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/12/2014Chardan CapitalBoost Price TargetBuy$100.00 -> $122.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2014Sanford C. BernsteinUpgradeMarket Perform -> Outperform$118.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Keefe, Bruyette & WoodsReiterated RatingOutperform$104.00 -> $107.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Medivation (NASDAQ:MDVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116$0.23$0.11$197.01 million$182.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415$0.25$0.29$373.85 million$377.74 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.33$0.35$236.70 million$260.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215$0.45$0.58$155.22 million$175.67 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115$0.27$0.17$149.00 million$129.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2015Q414$1.33$1.96$233.19 million$274.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314$0.84$0.96$182.00 million$200.48 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214$0.24$0.60$126.46 million$148.09 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.09)($0.18)$94.64 million$87.19 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q413($0.08)$0.03$72.68 million$96.61 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/30/2014Q4($0.14)($0.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q313($0.26)($0.18)$60.13 million$108.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2013Q2 2013($0.21)($0.07)$59.35 million$70.15 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.45)($0.36)$38.54 million$46.15 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2013Q4 2012($0.52)($0.43)$34.36 million$37.16 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2012Q312($0.03)($0.06)$52.11 million$64.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2012$0.23($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012$1.19$0.01ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2012($0.25)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2011($0.31)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/9/2011($0.25)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2011($0.24)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2011($0.17)($0.11)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Medivation (NASDAQ:MDVN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161$0.27$0.27$0.27
Q3 20161$0.32$0.32$0.32
Q4 20161$0.37$0.37$0.37
(Data provided by Zacks Investment Research)
Dividend History for Medivation (NASDAQ:MDVN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Medivation (NASDAQ:MDVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/6/2016Andrew Kenneth William PowellSVPSell2,578$60.42$155,762.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2016Rick BierlyCFOSell10,340$59.76$617,918.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Dawn SvoronosDirectorSell6,000$38.90$233,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016David HungCEOSell5,085$41.10$208,993.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Mohammad HirmandInsiderSell1,525$41.10$62,677.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Rick BierlyCFOSell2,998$40.00$119,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2016David HungCEOSell6,350$31.18$197,993.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/19/2016Clarence Patrick MachadoDirectorSell75,000$37.34$2,800,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Joseph M LobackiInsiderSell3,065$46.50$142,522.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2015W Anthony VernonDirectorBuy15,000$40.69$610,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015David HungCEOSell10,950$43.10$471,945.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2015Mohammad HirmandInsiderSell1,075$43.40$46,655.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Clarence Patrick MachadoDirectorSell71,980$42.36$3,049,072.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2015Dawn SvoronosDirectorSell3,100$89.15$276,365.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015Clarence Patrick MachadoDirectorSell36,000$117.43$4,227,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Rick BierlyCFOSell1,000$130.00$130,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/5/2015Rick BierlyCFOSell1,615$125.00$201,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2015Rick BierlyCFOSell2,170$124.70$270,599.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Rick BierlyCFOSell3,000$132.20$396,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Jennifer J RhodesInsiderSell1,390$130.92$181,978.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015David HungCEOSell100,891$120.83$12,190,659.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Dawn SvoronosDirectorSell3,350$119.75$401,162.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Jennifer J RhodesInsiderSell2,000$122.00$244,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2015Kathryn E FalbergDirectorBuy25,000$117.67$2,941,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2015David HungCEOSell19,109$120.12$2,295,373.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2015Jennifer J RhodesInsiderSell3,089$119.29$368,486.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2015David HungCEOSell3,190$100.48$320,531.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Clarence Patrick MachadoDirectorSell36,000$105.32$3,791,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015David HungCEOSell100,000$108.14$10,814,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014Clarence Patrick MachadoDirectorSell1,580$113.00$178,540.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2014David HungCEOSell5,420$113.00$612,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Lynn SeelyInsiderSell55,000$98.47$5,415,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Lynn SeelyInsiderSell20,000$94.60$1,892,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Lynn SeelyInsiderSell20,000$89.42$1,788,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Lynn SeelyInsiderSell20,000$83.62$1,672,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Lynn SeelyInsiderSell25,500$83.02$2,117,010.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/22/2014Lynn SeelyInsiderSell7,500$73.96$554,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2014Lynn SeelyInsiderSell12,000$79.02$948,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Lynn SeelyInsiderSell15,000$74.75$1,121,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Clarence Patrick MachadoCFOSell40,000$82.79$3,311,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2014Clarence Patrick MachadoCFOSell40,000$80.83$3,233,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Clarence Patrick MachadoCFOSell40,000$73.46$2,938,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2014Clarence Patrick MachadoCFOSell40,000$75.43$3,017,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2014David HungCEOSell150,000$73.50$11,025,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Clarence Patrick MachadoCFOSell40,000$76.29$3,051,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Jennifer RhodesInsiderSell14,000$76.28$1,067,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2013Clarence Patrick MachadoCFOSell5,425$62.66$339,930.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2013David HungCEOSell15,050$62.61$942,280.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/24/2013Cheryl CohenInsiderSell50,000$64.25$3,212,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/2/2013Cheryl CohenInsiderSell25,000$59.31$1,482,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/5/2013David HungCEOSell30,885$55.45$1,712,573.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/3/2013Cheryl CohenInsiderSell25,000$54.01$1,350,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/4/2012David HungCEOSell50,000$57.92$2,896,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Medivation (NASDAQ:MDVN)
DateHeadline
06/26/16 04:24 PMStrong Sell Calls Recommendations For Medivation, Inc. (NASDAQ:MDVN) At 0 - Investor Newswire
06/26/16 09:48 AMStock Performance to Track: Medivation, Inc. (NASDAQ:MDVN) - News Oracle
06/25/16 04:46 PMMedivation Becomes Oversold (MDVN)
06/25/16 08:54 AMStock Update (NASDAQ:MDVN): Glass Lewis Recommends Medivation Inc's Stockholders Support the Company's ... - Smarter Analyst
06/24/16 05:03 PMTwo Movers within Analysts Observation: Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) , Medivation, Inc ... - Street Updates
06/24/16 05:03 PMMedivation urges shareholders to reject Sanofi's bid - Seeking Alpha
06/24/16 01:46 PMGlass Lewis urges Medivation shareholders to support current board - June 24 (Reuters) - Medivation Inc said shareholder advisory firm Glass Lewis & Co has recommended the cancer drug maker's stockholders to not support Sanofi SA's efforts to replace the company's...
06/24/16 07:45 AMMedivation : Glass Lewis Recommends Medivation’s Stockholders Support the Company’s Current Board
06/24/16 07:45 AMMedivation (MDVN) Seeks to Set Record Straight on Sanofi's 'Misleading Claims'
06/24/16 07:40 AMGlass Lewis Recommends Medivation's Stockholders Support the Company's Current Board - [at noodls] - June 23, 2016 Reiterates Call for Stockholders to Reject Sanofi's Attempts to Force Through Its Grossly Inadequate Proposal SAN FRANCISCO--(BUSINESS WIRE)-- Medivation, Inc. (NASDAQ:MDVN) today sent a ...
06/24/16 07:37 AMMedivation urges shareholders to reject Sanofi's bid -
06/24/16 07:30 AMGlass Lewis Recommends Medivation’s Stockholders Support the Company’s Current Board - [Business Wire] - Medivation, Inc. today announced that independent proxy advisory firm Glass, Lewis & Co., LLC recommends that Medivation’s stockholders support the Company’s Board of Directors by rejecting Sanofi’s solicitation efforts.
06/23/16 05:19 PMMedivation Sends Letter to Stockholders to Set the Record Straight on Sanofi's Misleading Claims - [at noodls] - June 23, 2016 Reiterates Call for Stockholders to Reject Sanofi's Attempts to Force Through Its Grossly Inadequate Proposal SAN FRANCISCO--(BUSINESS WIRE)-- Medivation, Inc. (NASDAQ:MDVN) today sent a ...
06/23/16 04:50 PMMedivation Sends Letter to Stockholders to Set the Record Straight on Sanofi’s Misleading Claims - [Business Wire] - Medivation, Inc. today sent a letter to stockholders providing detailed information to correct the misleading claims Sanofi has made as part of its coercive efforts to acquire Medivation at an opportunistic, low price that substantially undervalues Medivation.
06/23/16 07:51 AMBenzinga's M&A Chatter for Wednesday June 22, 2016 - Benzinga
06/22/16 06:43 PMBenzinga's M&A Chatter for Wednesday June 22, 2016 - The following are the M&A deals, rumors and chatter circulating on Wall Street for Wednesday June 22, 2016: Sanofi May Add CVRs to Medivation Bid The Rumor:France's Sanofi (NYSE: SNY) is said to be adding contingent value rights or CVR's to its offer to acquire Medivation Inc. (NASDAQ: MDVN), according to sources as reported by Bloomberg on Wednesday. The CVR's would require Sanofi to make future payments based on ...Full story available on Benzinga.com
06/22/16 12:46 PMSanofi Said to Consider Adding Future Payments to Medivation Bid -
06/20/16 04:42 PMNIH won't cut price of taxpayer-funded prostate cancer drug -
06/20/16 05:52 AMAnalyst Views For The Week Ahead: Medivation, Inc. (NASDAQ:MDVN) - Fiscal Standard
06/20/16 05:52 AMStrong Buy Calls Count For Medivation, Inc. (NASDAQ:MDVN) At 9 - Investor Newswire
06/19/16 09:09 AMMedivation's (MDVN) Pidilizumab Positive in Phase I/II Study
06/17/16 07:53 AMMost Recent Stocks Movements: Medivation, Inc. (NASDAQ:MDVN) , Cempra, Inc. (NASDAQ:CEMP) - Street Updates
06/17/16 07:53 AMCompany Update (NASDAQ:MDVN): Medivation Inc's Pidilizumab Shows Potential Clinical Benefit and Safety in ... - Smarter Analyst
06/16/16 05:15 PMMedivation : Pidilizumab shows potential clinical benefit in children with DIPG
06/16/16 09:26 AMMedivation : Pidilizumab Shows Potential Clinical Benefit and Safety in Children With Diffuse Intrinsic Pontine Glioma (DIPG)
06/16/16 07:39 AMMedivation's Pidilizumab Shows Potential Clinical Benefit and Safety in Children With Diffuse Intrinsic Pontine Glioma (DIPG) - [at noodls] - June 13, 2016 Details Medivation's Track Record of Creating Enormous Stockholder Value Highlights the Potential of Medivation's Blockbuster XTANDI Franchise and Innovative Late Stage Pipeline to Create ...
06/16/16 06:01 AM7:01 am Medivation announces results from a Phase I/II study of pidilizumab; demonstrates potential clinical benefit in pediatric patients with diffuse intrinsic pontine glioma -
06/15/16 09:44 AMAnalysts Watching Stocks: Bristol-Myers Squibb Company (NYSE:BMY) , Medivation, Inc. (NASDAQ:MDVN) - Street Updates
06/15/16 09:44 AMHC Stocks Review: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Medivation Inc (NASDAQ:MDVN) - share market updates (press release)
06/15/16 09:44 AMThis Hot Stock is Trending: Medivation, Inc. (NASDAQ:MDVN) - News Oracle
06/15/16 09:44 AMAbbott Laboratories (NYSE:ABT) & Medivation Inc (NASDAQ:MDVN) Stocks in the News - Wall Street 24
06/14/16 07:30 PMMEDIVATION INVESTIGATION ALERT – Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches of Fiduciary Duty - MDVN - [Business Wire] - Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Medivation, Inc.
06/14/16 04:54 PMMEDIVATION : MDVN) Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach of Fiduciary Duty
06/14/16 09:53 AMSanofi Announces Expiration of Hart-Scott-Rodino Waiting Period Regarding Proposed Acquisition of Medivation
06/14/16 09:53 AMMEDIVATION, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
06/14/16 09:53 AMForm DFAN14A MEDIVATION, INC. Filed by: Sanofi
06/14/16 08:00 AMMedivation Has a Good Case for Patience -
06/13/16 04:46 PMSanofi Files Definitive Consent Solicitation to Remove and Replace Medivation's Board
06/13/16 04:46 PMSanofi Files Consent Solicitation To Remove And Replace Medivation's Board
06/13/16 04:46 PMSanofi (SNY) Files Consent Solicitation to Replace Medivation's (MDVN) Board, Mails Letter to Shareholders
06/13/16 04:32 PMMEDIVATION, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/13/16 04:01 PMMedivation Urges Shareholders to Reject Sanofi Proposal -
06/13/16 01:01 PMCORRECTED-UPDATE 1-Sanofi, Medivation advance to next phase of takeover fight - NEW YORK, June 13 (Reuters) - French drugmaker Sanofi and its takeover target Medivation Inc on Monday said they had filed official materials with the U.S. Securities and Exchange Commission, as...
06/13/16 09:54 AMSanofi moves ahead with plan to replace Medivation board -
06/13/16 07:59 AMMEDIVATION (MDVN) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Medivation, Inc. For ... - Yahoo Finance UK
06/13/16 07:39 AMMedivation Files Definitive Consent Revocation Statement and Mails Letter to Stockholders - [Business Wire] - Medivation, Inc. today announced that it has filed with the Securities and Exchange Commission a definitive Consent Revocation Statement. Medivation stockholders of record as of June 1, 2016 are eligible to submit consents or consent revocations by August 2, 2016.
06/13/16 07:07 AMMEDIVATION (MDVN) SHAREHOLDER ALERT – Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach of Fiduciary Duty - [Business Wire] - Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Medivation, Inc.
06/09/16 07:57 AMTwo Movers within Investors Observation: Medivation, Inc. (NASDAQ:MDVN) , DaVita healthCare Partners Inc. (NYSE ... - Street Updates
06/08/16 05:28 PMEarnings Report: Medivation, Inc. (NASDAQ:MDVN), Nordic American Tankers Limited (NYSE:NAT) - Beacon Chronicle
06/08/16 05:28 PMMEDIVATION INC. (NASDAQ:MDVN) Financial Condition Compared to S&P 500 - CML News
About Medivation

Medivation logoMedivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MDVN
  • CUSIP: 58501N10
Key Metrics:
  • Previous Close: $56.95
  • 50 Day Moving Average: $60.34
  • 200 Day Moving Average: $46.14
  • P/E Ratio: 38.25
  • P/E Growth: 1.25
  • Market Cap: $9.38B
  • Current Quarter EPS Consensus Estimate: $1.30 EPS
Additional Links:
Medivation (NASDAQ:MDVN) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha